Cover Image
Market Research Report

Company Profile: Bayer

Published by Datamonitor Healthcare Product code 603958
Published Content info 48 Pages
Delivery time: 1-2 business days
Price
Back to Top
Company Profile: Bayer
Published: December 13, 2017 Content info: 48 Pages
Description

Updated analysis and forecasts based on Q3 2017 company-reported sales.

PharmaVitae explores Bayer's prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016-26.

Snapshot:

  • Overview - Bayer's prescription drug sales will experience modest growth up to 2026.
  • Out to 2022 - Bayer's prescription drug sales will grow rapidly out to 2022, reaching total sales of $22.8bn.
  • Out to 2026 - Following major patent expiries in 2023, sales will marginally decline to $22.5bn in 2026.
  • Pipeline - Diabetic nephropathy treatment finerenone set for approval in 2020.
  • Events - Completion of Monsanto acquisition, and updates to Xarelto's label.

Highlights:

  • Bayer's prescription drug sales will experience modest growth up to 2026.
  • Genitourinary remains a key therapy area, despite little R&D involvement. Sales of contraceptive franchises Yaz and Mirena will drive sales in the segment.
  • Internal cardiovascular research will provide long-term sales growth.
  • Bayer's in-licensing strategy will continue to have moderate success.

Model updates:

  • Added vilaprisan
  • ODM-201 changed to darolutamide
  • Copanlisib changed to Aliqopa.

Analysis structure:

  • Explore and visualize revenue dynamics in Bayer's portfolio out to 2026 using 10-year in-house sales forecasts segmented by the following sections.

Company context:

  • How is Bayer strategically poised out to 2026?
  • What are Bayer's key strengths, weaknesses, opportunities, and threats?
  • What are Bayer's key catalysts during the current year?

Facts and figures:

  • What is Bayer's forecasted sales performance out to 2026?
  • What is the revenue trajectory of Bayer's current top 10 products out to 2026?
  • Which therapy areas will experience the largest growth and decline?
  • What are the portfolio weightings of Bayer based on the lifecycle of its products?

Key therapy areas:

  • Why will specific therapy areas experience the largest growth and decline?
  • What are the detailed competitive dynamics at play in Bayer's important therapeutic markets?
  • How is Bayer adapting strategically to internal and external headwinds?
Table of Contents
Product Code: DMKC0173328

TABLE OF CONTENTS

EXECUTIVE SUMMARY

Q3 2017 REVIEW

  • What were the highlights of Bayer's Q3 2017 earnings call?
  • Clinical update
  • Xarelto update

COMPANY CONTEXT

  • Bayer is aggressively pursuing the acquisition of Monsanto
  • Bayer's path towards becoming a life science company started with a CEO change
  • Bayer aims to speed up development in oncology
  • Bayer's 2016 earnings report sent mixed signals to investors
  • Bayer's SWOT analysis
  • Bayer's key upcoming events and catalysts

FACTS AND FIGURES

  • Bayer's prescription pharma sales outlook
  • Bayer's therapy area dynamics
  • Bayer's top 10 products over 2016-26
  • Bayer's growth drivers and resistors
  • Bayer's launch/core/expiry analysis
  • Bayer's financial outlook
  • Bayer's M&A history

KEY THERAPY AREAS

  • Genitourinary
  • Cardiovascular
  • Oncology

BIBLIOGRAPHY

LIST OF FIGURES

  • Figure 1: Bayer's prescription pharmaceutical sales ($m) and growth rate (%), 2013-26
  • Figure 2: Bayer's therapy area dynamics, 2016-26
  • Figure 3: Bayer's prescription pharmaceutical sales ($m) and growth rate (%), 2016-26
  • Figure 4: Bayer's launch/core/expiry portfolio configuration, 2016-26
  • Figure 5: Bayer's operating revenue/cost analysis ($m), 2009-21

LIST OF TABLES

  • Table 1: Bayer corporate structure
  • Table 2: Bayer's sales by therapy area ($m), 2016-26
  • Table 3: Bayer's key products, 2016-26
  • Table 4: Bayer's sales by launch, core, and expiry portfolio ($m), 2016-26
  • Table 5: Bayer's financial performance, 2015-21
  • Table 6: Bayer's key merger and acquisition deals, 2003-17
  • Table 7: Bayer's genitourinary portfolio ($m), 2016-26
  • Table 8: Bayer's cardiovascular portfolio ($m), 2016-26
  • Table 9: Bayer's oncology portfolio ($m), 2016-26
Back to Top